JAZZ (Drugmakers) Stock Valuation & Fair Value
Trading above its usual valuationJAZZ (Drugmakers) trades at a current P/E of 16.0, about 32% above its historical normal valuation, with a forward growth estimate of 42.2% and a PEG of 0.38. Analysts' one-year estimates have been hit 55% of the time. Priced at its historical normal P/E of 12.2 on the same blended earnings, the 2026-10-30 close of $215.98 corresponds to about $164 a share. This is a valuation reference, not a price target.
How to read these numbers: the PEG ratio and current P/E versus normal P/E.
Valuation flags
- Overvalued by 32%
Frequently asked questions
Is JAZZ overvalued?
At a current P/E of 16.0 versus its historical normal P/E of 12.2, JAZZ trades about 32% above its typical valuation, with a PEG of 0.38 on 42.2% forward growth. tickerseer currently rates it trading above its usual valuation.
What is JAZZ's fair value and PEG?
JAZZ trades at a current P/E of 16.0 against a historical normal P/E of 12.2, a PEG of 0.38, and a forward growth estimate of 42.2%. Priced at its historical normal P/E of 12.2 on the same blended earnings, the 2026-10-30 close of $215.98 corresponds to about $164 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of JAZZ changed?
tickerseer's rating has been trading above its usual valuation since 2026-10-31.
Industry: Drugmakers. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.